<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961363</url>
  </required_header>
  <id_info>
    <org_study_id>200904052M</org_study_id>
    <nct_id>NCT00961363</nct_id>
  </id_info>
  <brief_title>Effect of Sitagliptin in Impaired Glucose Tolerance</brief_title>
  <official_title>The Effect of Sitagliptin on Postprandial Glycemia and Endothelial Function in Chinese Subjects With Impaired Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and efficacy of sitagliptin 100 mg every&#xD;
      day (q.d.) in improving hyperglycemia and endothelial dysfunction in subjects with impaired&#xD;
      glucose tolerance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change in fasting and post-load plasma glucose levels during OGTT</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the changes in endothelial function, measured by circulating adhesion molecules</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the changes in beta cell functions derived from the glucose/insulin levels during OGTT</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the safety and the tolerability of sitagliptin, including clinical and laboratory adverse experiences, laboratory values, weight, and vital signs.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>sitagliptin 100 mg per day</description>
    <arm_group_label>Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chinese subjects aged 40-65 years with fasting plasma glucose &lt; 100 mg/dL and OGTT&#xD;
             2-hour glucose 140-199 mg/dL.&#xD;
&#xD;
          2. Subjects are judged to be in otherwise general good health based on medical history,&#xD;
             physical examination, and routine laboratory tests.&#xD;
&#xD;
          3. Subject has an understanding of the study procedures, alternative treatments available&#xD;
             and risk involved with the study, and voluntarily agrees to participate by giving&#xD;
             written informed consent.&#xD;
&#xD;
          4. Non-sterilized premenopausal female agrees to receive pregnancy test to confirm the&#xD;
             non-pregnancy status and use adequate contraceptive methods to prevent pregnancy&#xD;
             during the study period. Patient status should be confirmed by pregnancy test before&#xD;
             enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of diabetes (FPG&gt; 125 mg/dL, or OGTT 2-hour glucose&gt;=200 mg/dL, or current&#xD;
             use of an anti-diabetic agents, except for history of gestational diabetes).&#xD;
&#xD;
          2. History of intolerance or hypersensitivity or contraindication as mentioned in the&#xD;
             approved package insert (appendix).&#xD;
&#xD;
          3. Patient has any of the following disorders within the past 6 months: acute coronary&#xD;
             syndrome (e.g., MI or unstable angina), coronary artery intervention (e.g., CABG or&#xD;
             PTCA), stroke or transient ischemic neurological disorder.&#xD;
&#xD;
          4. Patient has new or worsening signs or symptoms of coronary heart disease within the&#xD;
             past 3 months.&#xD;
&#xD;
          5. Patient has a BMI &gt; 40 kg/m2.&#xD;
&#xD;
          6. Patient is on or likely to require more than 14 consecutive days or repeated courses&#xD;
             of pharmacologic doses of corticosteroids. Note: inhaled, nasal, and topical&#xD;
             corticosteroids are permitted.&#xD;
&#xD;
          7. Patient is on or likely to require treatment with immunosuppressive agents (e.g.,&#xD;
             cyclosporine, methotrexate).&#xD;
&#xD;
          8. Advanced renal insufficiency (estimated creatinine clearance &lt; 50 ml/min).&#xD;
&#xD;
          9. Severe hepatic insufficiency (Child-Pugh score &gt; 9, see Appendix).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee-Ming Chuang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lee-Ming Chuang, MD, PhD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>65038</phone_ext>
    <email>leeming@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee-Ming Chuang, MD, PhD</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>65038</phone_ext>
      <email>leeming@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Lee-Ming Chuang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hung-Yuan Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hung-Ju Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chia-Hsiung Chang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shyang-Rong Shih, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tien-Jyun Chang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaw-Shiun Tsai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>August 11, 2009</study_first_submitted>
  <study_first_submitted_qc>August 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <last_update_submitted>March 19, 2010</last_update_submitted>
  <last_update_submitted_qc>March 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Professor Lee-Ming Chuang</name_title>
    <organization>National Taiwan Univerisity Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

